RNA Outsourcing Resources
-
Gene And Cell Therapy: Planning For Manufacturing Success Early
1/16/2023
As gene therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations, explore how to optimize plasmid production and reach patients with efficiency.
-
Optimizing AAV8 Capsid Purification With Oversized GOI
6/2/2025
Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.
-
Optimization Of rAAV Production Using An In-House Suspension HEK293 Cell Line
6/2/2025
Boost rAAV yields and quality while reducing costs with our proprietary HEK293 cell line and scalable, optimized manufacturing platform for gene therapy.
-
mRNA Synthesis Reagents And Manufacturing
8/14/2023
As novel mRNA therapies are starting to enter clinical stages of development, Aldevron is providing critical support in a number of ways with specialized products and services.
-
Expression Analysis Of CTLA-4, PD-1, And PD-L1
4/23/2025
Advance personalized immunotherapy in NSCLC by leveraging qPCR-based analysis of CTLA-4, PD-1, and PD-L1 expression to identify predictive biomarkers and guide more effective treatment strategies.
-
Accelerated Development: Gene Therapy Vs. Small Molecule
12/26/2023
Combined with the inherent difficulty of the chemistry behind gene therapy development, its pace, structure, and funding dynamics are unique among treatment modalities.
-
Phase IIb Trial: Evaluating A Novel Treatment For Locally Advanced Or Metastatic Breast Cancer
12/5/2024
This case study highlights a successful Phase IIb clinical trial conducted by an Indian biotech company evaluating a novel treatment for Locally Advanced or Metastatic Breast Cancer.
-
Expectations On The Pathway To GMP For Gene-Modified Cell Therapies
6/21/2023
Learn how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining regulatory compliance.